董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Louis Lange | 男 | Director | 71 | 未披露 | 未持股 | 2020-04-01 |
| Gerald L. Chan | 男 | Director, Chairman of the Board | 69 | 未披露 | 未持股 | 2020-04-01 |
| Lu Huang | 女 | Director | 46 | 未披露 | 未持股 | 2020-04-01 |
| Francis W. Chen | 男 | Director | 71 | 未披露 | 未持股 | 2020-04-01 |
| Irene McCarthy | 女 | Chief Executive Officer, Director | 55 | 未披露 | 未持股 | 2020-04-01 |
| Edward P. Owens | 男 | Director | 73 | 未披露 | 未持股 | 2020-04-01 |
| Kevin F. McLaughlin | 男 | Director | 63 | 未披露 | 未持股 | 2020-04-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brian D. Blakey | 男 | Chief Business Officer | 58 | 未披露 | 未持股 | 2020-04-01 |
| James R. Carr | -- | Chief Clinical Development Officer | 57 | 未披露 | 未持股 | 2020-04-01 |
| Irene McCarthy | 女 | Chief Executive Officer, Director | 55 | 未披露 | 未持股 | 2020-04-01 |
| Robert Weiskopf | 男 | Chief Financial Officer | 69 | 未披露 | 未持股 | 2020-04-01 |
董事简历
中英对照 | 中文 | 英文- Louis Lange
-
Louis Lange，医学博士，自2022年9月起担任Epiphany Technology Acquisition Corp.的董事之一，作为生物技术领域领先的企业家、投资者和学术带头人，拥有漫长而卓越的职业生涯。Lange博士于1992年创立了CV Therapeutics，Inc.“CVT”和Nasdaq：CVTX，一家专注于心血管疾病的生物技术公司，并担任其董事长、首席执行官和首席科学官。Lange博士在获得5000万美元风险投资后，于1996年首次公开发行CVT，并监督了CVT的商业成功，引领了Ranexa和Lexiscan的增长，这两种药物的年销售额合计超过15亿美元。2009年，Lange博士将CVT以14亿美元的价格卖给了吉利德科学公司（Nasdaq：GILD），并在2019年之前一直担任兼职，担任高级顾问，在2018年之前向吉利德科学公司的首席执行官汇报工作。在成功销售CVT之后，Lange博士创立并出售了另外两家生物技术公司。2017年，GE Healthcare收购了其中一家公司Rapidscan Pharma Solutions Inc.（“RPS”），后者是一家用于心血管疾病诊断的生物制药应激剂开发商。2015年，Audentes Therapeutics, Inc.（Nasdaq：BOLD）收购了其中的第二家公司——基因治疗产品开发商Cardiogen Sciences，Inc；Lange博士继续担任首席董事，直到2020年以31亿美元将Audentes Therapeutics出售给Astellas Pharma Inc.（TYO：4503）。目前，Lange博士是Asset Management Ventures（以下简称“AMV”）的合伙人，该公司是一家早期风险投资公司，专注于数字健康、技术和生命科学领域的投资，处于生物技术领域关键创新趋势和交易流程的前沿。兰格博士在生物技术公司的各个领域领导了超过12项投资。除了Lange博士的运营和投资经验外，Lange博士在哈佛大学和华盛顿大学的学术医学领域工作了22年，他曾于1985-1992年在华盛顿大学医学院的犹太医院担任心脏病学主任和医学教授，并且是分子心脏病学领域的首批院士之一。目前，Lange博士担任罗切斯特大学董事会成员，自1998年以来一直担任这一职务。作为负责监督所有医疗业务的卫生事务委员会主席，Lange博士一直是医疗中心战略振兴领导团队的一员，负责监督项目，包括建造两座研究大楼和招聘100多名教职员工。Lange还领导了生物技术领域最受尊敬的行业和行业协会。从1999年到2009年，Lange博士担任生物技术创新组织的董事会成员，该组织是生物技术公司的贸易组织，领导了最大的成员公司委员会两年。Lange博士曾在非营利和营利性领域的许多其他公共和私人委员会任职，包括系统生物学研究所（“ISB”）和加州大学旧金山分校格拉德斯通研究所（UCSF Gladstone Institute），这是一个独立的、非营利性的生命科学研究机构，位于旧金山湾区生物医学和技术创新的中心。Lange拥有罗切斯特大学的学士学位、哈佛大学的医学博士学位和哈佛大学的生物化学博士学位。
Louis Lange, M.D., Ph.D., one of Epiphany Technology Acquisition Corp.'s Directors since September 2022 has a long and distinguished career as a leading entrepreneur, investor, and academic leader in the biotechnology sector. Dr. Lange founded CV Therapeutics, Inc. "CVT" and Nasdaq: CVTX, a biotechnology company focused on cardiovascular diseases, in 1992 and served as its chairman, chief executive officer and chief scientific officer. Dr. Lange led the initial public offering of CVT in 1996 after $50 million in venture investments and oversaw the commercial success of CVT, spearheading the growth of Ranexa and Lexiscan, two drugs with combined annual sales in excess of $1.5 billion dollars. Dr. Lange led the sale of CVT to Gilead Sciences, Inc. (Nasdaq: GILD) in 2009 for $1.4 billion, and stayed on part time until 2019 as a Senior Advisor reporting until 2018 to the Chief Executive Officer of Gilead Sciences. After successfully selling CVT, Dr. Lange founded and sold two additional biotechnology companies. In 2017 GE Healthcare acquired one of these companies, Rapidscan Pharma Solutions Inc. ("RPS"), a developer of a biopharmaceutical stress agent used in the diagnosis of cardiovascular disease. In 2015 Audentes Therapeutics, Inc. (Nasdaq: BOLD) acquired the second of these companies, gene therapy products developer Cardiogen Sciences, Inc.; Dr. Lange stayed on as lead director up to the sale of Audentes Therapeutics to Astellas Pharma Inc. (TYO:4503) in 2020 for $3.1 billion. Currently, Dr. Lange is a Partner at Asset Management Ventures ("AMV"), an early-stage venture capital firm focused on investments in the digital health, technology, and life sciences sectors, sitting at the forefront of key innovation trends and deal flow within the biotechnology space. Dr. Lange has led over 12 investments across all areas of biotechnology companies.In addition to Dr. Lange's operational and investing experience, Dr. Lange spent 22 years in academic medicine at Harvard University and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital at Washington University School of Medicine from 1985-1992 and was one of the first academicians in molecular cardiology. Currently, Dr. Lange serves as a member of the Board of Trustees at the University of Rochester, a role he has held since 1998. As Chair of the Health Affairs committee that oversees all of the medical operations, Dr. Lange has been part of the leadership team for strategic re-invigoration of the medical center, overseeing projects including construction of two research buildings and recruitment of over 100 faculty members.Dr. Lange has also led the most respected industry and trade associations in the biotechnology sector. From 1999 to 2009 Dr. Lange served on the Board of Directors of Biotechnology Innovation Organization, the trade organization of biotechnology companies, leading the largest committee of member companies for two years. Dr. Lange has been on numerous other public and private Boards in both the non-profit and for-profit arena, including the Institute of Systems Biology ("ISB"), a nonprofit biomedical research organization co-founded by industry stalwart Dr. Leroy ("Lee") Hood, and the UCSF Gladstone Institute, an independent, nonprofit life science research organization located in the epicenter of biomedical and technological innovation in the San Francisco Bay Area.Dr. Lange has a Bachelor's degree from the University of Rochester, an M.D. from Harvard University and a Ph.D. in Biological Chemistry, also from Harvard University. - Louis Lange，医学博士，自2022年9月起担任Epiphany Technology Acquisition Corp.的董事之一，作为生物技术领域领先的企业家、投资者和学术带头人，拥有漫长而卓越的职业生涯。Lange博士于1992年创立了CV Therapeutics，Inc.“CVT”和Nasdaq：CVTX，一家专注于心血管疾病的生物技术公司，并担任其董事长、首席执行官和首席科学官。Lange博士在获得5000万美元风险投资后，于1996年首次公开发行CVT，并监督了CVT的商业成功，引领了Ranexa和Lexiscan的增长，这两种药物的年销售额合计超过15亿美元。2009年，Lange博士将CVT以14亿美元的价格卖给了吉利德科学公司（Nasdaq：GILD），并在2019年之前一直担任兼职，担任高级顾问，在2018年之前向吉利德科学公司的首席执行官汇报工作。在成功销售CVT之后，Lange博士创立并出售了另外两家生物技术公司。2017年，GE Healthcare收购了其中一家公司Rapidscan Pharma Solutions Inc.（“RPS”），后者是一家用于心血管疾病诊断的生物制药应激剂开发商。2015年，Audentes Therapeutics, Inc.（Nasdaq：BOLD）收购了其中的第二家公司——基因治疗产品开发商Cardiogen Sciences，Inc；Lange博士继续担任首席董事，直到2020年以31亿美元将Audentes Therapeutics出售给Astellas Pharma Inc.（TYO：4503）。目前，Lange博士是Asset Management Ventures（以下简称“AMV”）的合伙人，该公司是一家早期风险投资公司，专注于数字健康、技术和生命科学领域的投资，处于生物技术领域关键创新趋势和交易流程的前沿。兰格博士在生物技术公司的各个领域领导了超过12项投资。除了Lange博士的运营和投资经验外，Lange博士在哈佛大学和华盛顿大学的学术医学领域工作了22年，他曾于1985-1992年在华盛顿大学医学院的犹太医院担任心脏病学主任和医学教授，并且是分子心脏病学领域的首批院士之一。目前，Lange博士担任罗切斯特大学董事会成员，自1998年以来一直担任这一职务。作为负责监督所有医疗业务的卫生事务委员会主席，Lange博士一直是医疗中心战略振兴领导团队的一员，负责监督项目，包括建造两座研究大楼和招聘100多名教职员工。Lange还领导了生物技术领域最受尊敬的行业和行业协会。从1999年到2009年，Lange博士担任生物技术创新组织的董事会成员，该组织是生物技术公司的贸易组织，领导了最大的成员公司委员会两年。Lange博士曾在非营利和营利性领域的许多其他公共和私人委员会任职，包括系统生物学研究所（“ISB”）和加州大学旧金山分校格拉德斯通研究所（UCSF Gladstone Institute），这是一个独立的、非营利性的生命科学研究机构，位于旧金山湾区生物医学和技术创新的中心。Lange拥有罗切斯特大学的学士学位、哈佛大学的医学博士学位和哈佛大学的生物化学博士学位。
- Louis Lange, M.D., Ph.D., one of Epiphany Technology Acquisition Corp.'s Directors since September 2022 has a long and distinguished career as a leading entrepreneur, investor, and academic leader in the biotechnology sector. Dr. Lange founded CV Therapeutics, Inc. "CVT" and Nasdaq: CVTX, a biotechnology company focused on cardiovascular diseases, in 1992 and served as its chairman, chief executive officer and chief scientific officer. Dr. Lange led the initial public offering of CVT in 1996 after $50 million in venture investments and oversaw the commercial success of CVT, spearheading the growth of Ranexa and Lexiscan, two drugs with combined annual sales in excess of $1.5 billion dollars. Dr. Lange led the sale of CVT to Gilead Sciences, Inc. (Nasdaq: GILD) in 2009 for $1.4 billion, and stayed on part time until 2019 as a Senior Advisor reporting until 2018 to the Chief Executive Officer of Gilead Sciences. After successfully selling CVT, Dr. Lange founded and sold two additional biotechnology companies. In 2017 GE Healthcare acquired one of these companies, Rapidscan Pharma Solutions Inc. ("RPS"), a developer of a biopharmaceutical stress agent used in the diagnosis of cardiovascular disease. In 2015 Audentes Therapeutics, Inc. (Nasdaq: BOLD) acquired the second of these companies, gene therapy products developer Cardiogen Sciences, Inc.; Dr. Lange stayed on as lead director up to the sale of Audentes Therapeutics to Astellas Pharma Inc. (TYO:4503) in 2020 for $3.1 billion. Currently, Dr. Lange is a Partner at Asset Management Ventures ("AMV"), an early-stage venture capital firm focused on investments in the digital health, technology, and life sciences sectors, sitting at the forefront of key innovation trends and deal flow within the biotechnology space. Dr. Lange has led over 12 investments across all areas of biotechnology companies.In addition to Dr. Lange's operational and investing experience, Dr. Lange spent 22 years in academic medicine at Harvard University and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital at Washington University School of Medicine from 1985-1992 and was one of the first academicians in molecular cardiology. Currently, Dr. Lange serves as a member of the Board of Trustees at the University of Rochester, a role he has held since 1998. As Chair of the Health Affairs committee that oversees all of the medical operations, Dr. Lange has been part of the leadership team for strategic re-invigoration of the medical center, overseeing projects including construction of two research buildings and recruitment of over 100 faculty members.Dr. Lange has also led the most respected industry and trade associations in the biotechnology sector. From 1999 to 2009 Dr. Lange served on the Board of Directors of Biotechnology Innovation Organization, the trade organization of biotechnology companies, leading the largest committee of member companies for two years. Dr. Lange has been on numerous other public and private Boards in both the non-profit and for-profit arena, including the Institute of Systems Biology ("ISB"), a nonprofit biomedical research organization co-founded by industry stalwart Dr. Leroy ("Lee") Hood, and the UCSF Gladstone Institute, an independent, nonprofit life science research organization located in the epicenter of biomedical and technological innovation in the San Francisco Bay Area.Dr. Lange has a Bachelor's degree from the University of Rochester, an M.D. from Harvard University and a Ph.D. in Biological Chemistry, also from Harvard University.
- Gerald L. Chan
-
GeraldL.Chan于2018年6月被任命为Stealth BioTherapeutics Corp董事兼董事长。他自2007年10月起担任Stealth Delaware的董事。Chan博士于1986年联合创立了The Morningside Group。他自1986年起担任恒隆集团有限公司董事会成员。他曾任职于Aduro Biotech Inc.的董事会。纳斯达克股票代码:ADRO从2014年到2018年，目前担任ApellisPharmaceuticals，Inc.（纳斯达克股票代码:APLS）的成员和董事会主席。Chan博士在加州大学洛杉矶分校（University of California，Los Angeles）获得工程学学士学位和硕士学位，并获得医学放射物理学硕士学位和理学博士学位。哈佛大学放射生物学学士学位。他在达纳-法伯癌症研究所（Dana-Farber Cancer Institute）做博士后培训，是美国白血病协会（the Leukemia Society of America）的研究员。
Gerald L. Chan was appointed as a Director of Stealth BioTherapeutics Corp and as Chairman of the Board in June 2018. He has served as a director of Stealth Delaware since October 2007. Dr. Chan co-founded the Morningside group in 1986. He has been a member of the board of directors of Hang Lung Group Limited since 1986. He served on the board of directors of Aduro Biotech Inc. Nasdaq: ADRO from 2014 until 2018 and currently serves as a member and the chairman of the board of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Dr. Chan received a B.S. and M.S. in engineering from the University of California, Los Angeles, and a M.S. in medical radiological physics and an Sc.D. in radiation biology from Harvard University. He did his post-doctoral training at the Dana-Farber Cancer Institute as a fellow of the Leukemia Society of America. - GeraldL.Chan于2018年6月被任命为Stealth BioTherapeutics Corp董事兼董事长。他自2007年10月起担任Stealth Delaware的董事。Chan博士于1986年联合创立了The Morningside Group。他自1986年起担任恒隆集团有限公司董事会成员。他曾任职于Aduro Biotech Inc.的董事会。纳斯达克股票代码:ADRO从2014年到2018年，目前担任ApellisPharmaceuticals，Inc.（纳斯达克股票代码:APLS）的成员和董事会主席。Chan博士在加州大学洛杉矶分校（University of California，Los Angeles）获得工程学学士学位和硕士学位，并获得医学放射物理学硕士学位和理学博士学位。哈佛大学放射生物学学士学位。他在达纳-法伯癌症研究所（Dana-Farber Cancer Institute）做博士后培训，是美国白血病协会（the Leukemia Society of America）的研究员。
- Gerald L. Chan was appointed as a Director of Stealth BioTherapeutics Corp and as Chairman of the Board in June 2018. He has served as a director of Stealth Delaware since October 2007. Dr. Chan co-founded the Morningside group in 1986. He has been a member of the board of directors of Hang Lung Group Limited since 1986. He served on the board of directors of Aduro Biotech Inc. Nasdaq: ADRO from 2014 until 2018 and currently serves as a member and the chairman of the board of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Dr. Chan received a B.S. and M.S. in engineering from the University of California, Los Angeles, and a M.S. in medical radiological physics and an Sc.D. in radiation biology from Harvard University. He did his post-doctoral training at the Dana-Farber Cancer Institute as a fellow of the Leukemia Society of America.
- Lu Huang
-
Lu Huang于2018年6月被任命为Stealth BioTherapeutics Corp董事。黄博士于2003年10月加入晨兴集团，并领导晨兴生命科学在中国的投资团队。她领导了十几项在中国的梦百合和生命科学投资，并在包括Micurx Pharmaceuticals，Inc.在内的多家投资组合公司担任董事。黄博士在上海交通大学医学院（原名上海第二医科大学）获得医学博士学位，随后在大学附属医院工作。她持有圣约翰大学的工商管理硕士学位。
Lu Huang has served as a member of LumiraDx's board of directors since October 2018. Dr. Huang joined Morningside in 2003 and is currently in charge of Morningside Ventures' healthcare investment activities in China. With over 19 years' experience in the venture capital industry, she has led more than 30 healthcare/life science investments in greater China and North America, ranging from bio-pharmaceutical, medical devices and in-vitro diagnostics sectors to healthcare services and IT. Before joining Morningside, Dr. Huang served as a Marketing Associate in the Public Relations & Marketing group at Continuum Health Partners in New York City, which provides integrated healthcare management services throughout the New York metropolitan region. Dr. Huang previously served on the board of directors of Stealth BioTherapeutics Corp., a publicly traded biotechnology company, from June 2018 to December 2020. Dr. Huang obtained her M.D. from Shanghai Jiao Tong University School of Medicine formerly known as Shanghai Second Medical University and subsequently worked at the University affiliated hospital. She holds an M.B.A. from St. John's University. - Lu Huang于2018年6月被任命为Stealth BioTherapeutics Corp董事。黄博士于2003年10月加入晨兴集团，并领导晨兴生命科学在中国的投资团队。她领导了十几项在中国的梦百合和生命科学投资，并在包括Micurx Pharmaceuticals，Inc.在内的多家投资组合公司担任董事。黄博士在上海交通大学医学院（原名上海第二医科大学）获得医学博士学位，随后在大学附属医院工作。她持有圣约翰大学的工商管理硕士学位。
- Lu Huang has served as a member of LumiraDx's board of directors since October 2018. Dr. Huang joined Morningside in 2003 and is currently in charge of Morningside Ventures' healthcare investment activities in China. With over 19 years' experience in the venture capital industry, she has led more than 30 healthcare/life science investments in greater China and North America, ranging from bio-pharmaceutical, medical devices and in-vitro diagnostics sectors to healthcare services and IT. Before joining Morningside, Dr. Huang served as a Marketing Associate in the Public Relations & Marketing group at Continuum Health Partners in New York City, which provides integrated healthcare management services throughout the New York metropolitan region. Dr. Huang previously served on the board of directors of Stealth BioTherapeutics Corp., a publicly traded biotechnology company, from June 2018 to December 2020. Dr. Huang obtained her M.D. from Shanghai Jiao Tong University School of Medicine formerly known as Shanghai Second Medical University and subsequently worked at the University affiliated hospital. She holds an M.B.A. from St. John's University.
- Francis W. Chen
-
FrancisW.Chen于2018年6月被任命为Stealth BioTherapeutics Corp董事。他自2006年4月起担任Stealth Delaware的董事。他于2011年11月创立SinoAmerican Partners Limited公司（咨询服务公司，专门从事涉及自然资源、基于运输的资产和相关金融服务的跨境交易），目前担任其主席。陈博士还曾于2009年6月至2012年12月担任WI Harper Group（一家早期风险投资公司，在硅谷和中国开展投资活动）的风险合伙人。他曾于2009年11月至2013年8月担任SPI绿能宝能源互联网股份公司董事会成员。陈博士在梦百合行业拥有超过20年的管理经验，并曾在多家私营公司的董事会任职。Chen博士拥有Harvard University免疫学博士学位和Tufts University化学硕士学位和B.S.学位。
Francis W. Chen was appointed as a Director of Stealth BioTherapeutics Corp in June 2018. He has served as a director of Stealth Delaware since April 2006. In November 2011 he founded, and currently serves as the chairman of, SinoAmerican Partners Limited, an advisory services firm that specializes in cross-border transactions involving natural resources, transportation-based assets and related financial services. Dr. Chen was also a venture partner at WI Harper Group, an early-stage venture capital firm with investment activities in Silicon Valley and China from June 2009 to December 2012. He previously served on the board of directors of SPI Energy Co., Ltd. from November 2009 to August 2013. Dr. Chen has more than 20 years of prior management experience in the healthcare industry and has served on the board of directors of several private companies. Dr. Chen holds a Ph.D. in immunology from Harvard University and an M.S. and a B.S. in chemistry from Tufts University. - FrancisW.Chen于2018年6月被任命为Stealth BioTherapeutics Corp董事。他自2006年4月起担任Stealth Delaware的董事。他于2011年11月创立SinoAmerican Partners Limited公司（咨询服务公司，专门从事涉及自然资源、基于运输的资产和相关金融服务的跨境交易），目前担任其主席。陈博士还曾于2009年6月至2012年12月担任WI Harper Group（一家早期风险投资公司，在硅谷和中国开展投资活动）的风险合伙人。他曾于2009年11月至2013年8月担任SPI绿能宝能源互联网股份公司董事会成员。陈博士在梦百合行业拥有超过20年的管理经验，并曾在多家私营公司的董事会任职。Chen博士拥有Harvard University免疫学博士学位和Tufts University化学硕士学位和B.S.学位。
- Francis W. Chen was appointed as a Director of Stealth BioTherapeutics Corp in June 2018. He has served as a director of Stealth Delaware since April 2006. In November 2011 he founded, and currently serves as the chairman of, SinoAmerican Partners Limited, an advisory services firm that specializes in cross-border transactions involving natural resources, transportation-based assets and related financial services. Dr. Chen was also a venture partner at WI Harper Group, an early-stage venture capital firm with investment activities in Silicon Valley and China from June 2009 to December 2012. He previously served on the board of directors of SPI Energy Co., Ltd. from November 2009 to August 2013. Dr. Chen has more than 20 years of prior management experience in the healthcare industry and has served on the board of directors of several private companies. Dr. Chen holds a Ph.D. in immunology from Harvard University and an M.S. and a B.S. in chemistry from Tufts University.
- Irene McCarthy
-
Irene McCarthy自2018年6月起担任Stealth BioTherapeutics Corp董事，自2018年10月起担任Stealth BioTherapeutics Corp首席执行官。她曾一直担任Stealth Delaware公司的首席执行官（2016年2月以来）、Stealth Delaware公司的总裁兼秘书（2015年8月以来）、Stealth Delaware公司的董事（2009年7月以来）。在加入Stealth之前，McCarthy女士于2009年1月至2016年4月担任Morningside Technology Advisory，LLC及其附属公司（一家私人咨询公司）的投资团队成员，她仍担任Morningside Technology Advisory，LLC的董事。她曾担任众多私营生物技术公司的董事，开发广泛的治疗重点领域的药物。她持有宾夕法尼亚大学法学院（the University of Pennsylvania Law School）的法学博士学位和贝茨学院（Bates College）的英语和政治学学士学位。
Irene McCarthy has served as a Director of Stealth BioTherapeutics Corp since June 2018 and as Chief Executive Officer of Stealth BioTherapeutics Corp since October 2018. She has served as Chief Executive Officer of Stealth Delaware since February 2016 as President and Secretary of Stealth Delaware since August 2015 and as a director of Stealth Delaware since July 2009. Prior to Stealth, Ms. McCarthy was a member of the investment team at Morningside Technology Advisory, LLC and affiliates, a private advisory company, from January 2009 to April 2016 and she remains a director of Morningside Technology Advisory, LLC. She has served as a director for numerous private biotechnology companies developing drugs across a broad spectrum of therapeutic focus areas. She holds a J.D. from the University of Pennsylvania Law School and a B.A. in English and Political Science from Bates College. - Irene McCarthy自2018年6月起担任Stealth BioTherapeutics Corp董事，自2018年10月起担任Stealth BioTherapeutics Corp首席执行官。她曾一直担任Stealth Delaware公司的首席执行官（2016年2月以来）、Stealth Delaware公司的总裁兼秘书（2015年8月以来）、Stealth Delaware公司的董事（2009年7月以来）。在加入Stealth之前，McCarthy女士于2009年1月至2016年4月担任Morningside Technology Advisory，LLC及其附属公司（一家私人咨询公司）的投资团队成员，她仍担任Morningside Technology Advisory，LLC的董事。她曾担任众多私营生物技术公司的董事，开发广泛的治疗重点领域的药物。她持有宾夕法尼亚大学法学院（the University of Pennsylvania Law School）的法学博士学位和贝茨学院（Bates College）的英语和政治学学士学位。
- Irene McCarthy has served as a Director of Stealth BioTherapeutics Corp since June 2018 and as Chief Executive Officer of Stealth BioTherapeutics Corp since October 2018. She has served as Chief Executive Officer of Stealth Delaware since February 2016 as President and Secretary of Stealth Delaware since August 2015 and as a director of Stealth Delaware since July 2009. Prior to Stealth, Ms. McCarthy was a member of the investment team at Morningside Technology Advisory, LLC and affiliates, a private advisory company, from January 2009 to April 2016 and she remains a director of Morningside Technology Advisory, LLC. She has served as a director for numerous private biotechnology companies developing drugs across a broad spectrum of therapeutic focus areas. She holds a J.D. from the University of Pennsylvania Law School and a B.A. in English and Political Science from Bates College.
- Edward P. Owens
-
Edward P. Owens，自2013年起，他一直担任董事。他曾担任 Wellington Management Company, LLP 的合伙人，投资组合经理和全球行业分析师，在该公司，自1974年起他一直在证券投资管理部门工作。自1984年5月the Vanguard Health Care Fund 成立起至2012年12月他从Wellington退休，他担任证券投资组合经理28年。他持有University of Virginia的物理学学士学位，以及 Harvard Business School。的工商管理学硕士学位。
Edward P. Owens was previously partner, portfolio manager and global industry analyst with Wellington Management Company, LLP where he worked in investment management from 1974 to 2012. He was the portfolio manager of the Vanguard Health Care Fund for 28 years from its inception in May 1984 until his retirement from Wellington in December 2012.Mr. Owens serves on the board of directors of Stealth BioTherapeutics Corp. He has a B.S. in physics from the University of Virginia and an M.B.A. from Harvard Business School. - Edward P. Owens，自2013年起，他一直担任董事。他曾担任 Wellington Management Company, LLP 的合伙人，投资组合经理和全球行业分析师，在该公司，自1974年起他一直在证券投资管理部门工作。自1984年5月the Vanguard Health Care Fund 成立起至2012年12月他从Wellington退休，他担任证券投资组合经理28年。他持有University of Virginia的物理学学士学位，以及 Harvard Business School。的工商管理学硕士学位。
- Edward P. Owens was previously partner, portfolio manager and global industry analyst with Wellington Management Company, LLP where he worked in investment management from 1974 to 2012. He was the portfolio manager of the Vanguard Health Care Fund for 28 years from its inception in May 1984 until his retirement from Wellington in December 2012.Mr. Owens serves on the board of directors of Stealth BioTherapeutics Corp. He has a B.S. in physics from the University of Virginia and an M.B.A. from Harvard Business School.
- Kevin F. McLaughlin
-
Kevin F. McLaughlin ，他于2010年11月加入Acceleron公司。他是我们的高级副总裁、首席财务官和财务主管。他最近担任Qteros公司的高级副总裁兼首席财务官（从2009年到2010年）。他曾担任Aptius Education公司的共同创始人，以及首席运营官和董事（从2007年到2009年）。从1996年到2007年，他曾担任PRAECIS Pharmaceuticals公司的多种执行职务。他曾加入PRAECIS公司，担任他们的第一首席财务官，在那里他负责私人融资、融资合作、该公司的首次公开发行（ipo）和后续股票发行。此后，他成为公司的首席运营官、总裁兼首席执行官。他曾担任董事会成员。他负责公司销售给GlaxoSmithKline公司的谈判。他的职业生涯始于Prime Computer和Computervision Corporation的高级财务职务。他持有美国东北大学 （Northeastern University）的商业学士学位，以及Babson College的工商管理硕士学位。
Kevin F. McLaughlin was appointed as a Director of Stealth BioTherapeutics Corp in June 2018. He has served as a director of Stealth Delaware since March 2017. Mr. McLaughlin is currently Senior Vice President, Chief Financial Officer and Treasurer of Acceleron Pharma, Inc., a biotechnology company, and has been since November 2010. Mr. McLaughlin has also served on the board of directors of Vericel Corporation, a biopharmaceutical company, since January 2015. He previously served as Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company, from 2009 through 2010 and as co-founder, Chief Operating Officer and director of Aptius Education, Inc., a publishing company, from 2007 through 2009. Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc., a biopharmaceutical company, from 1996 through 2007 initially as Chief Financial Officer, before becoming Chief Operating Officer and eventually President and Chief Executive Officer, and he served as a member of the board of directors. Mr. McLaughlin began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin received a B.S. in business from Northeastern University and an M.B.A. from Babson College. - Kevin F. McLaughlin ，他于2010年11月加入Acceleron公司。他是我们的高级副总裁、首席财务官和财务主管。他最近担任Qteros公司的高级副总裁兼首席财务官（从2009年到2010年）。他曾担任Aptius Education公司的共同创始人，以及首席运营官和董事（从2007年到2009年）。从1996年到2007年，他曾担任PRAECIS Pharmaceuticals公司的多种执行职务。他曾加入PRAECIS公司，担任他们的第一首席财务官，在那里他负责私人融资、融资合作、该公司的首次公开发行（ipo）和后续股票发行。此后，他成为公司的首席运营官、总裁兼首席执行官。他曾担任董事会成员。他负责公司销售给GlaxoSmithKline公司的谈判。他的职业生涯始于Prime Computer和Computervision Corporation的高级财务职务。他持有美国东北大学 （Northeastern University）的商业学士学位，以及Babson College的工商管理硕士学位。
- Kevin F. McLaughlin was appointed as a Director of Stealth BioTherapeutics Corp in June 2018. He has served as a director of Stealth Delaware since March 2017. Mr. McLaughlin is currently Senior Vice President, Chief Financial Officer and Treasurer of Acceleron Pharma, Inc., a biotechnology company, and has been since November 2010. Mr. McLaughlin has also served on the board of directors of Vericel Corporation, a biopharmaceutical company, since January 2015. He previously served as Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company, from 2009 through 2010 and as co-founder, Chief Operating Officer and director of Aptius Education, Inc., a publishing company, from 2007 through 2009. Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc., a biopharmaceutical company, from 1996 through 2007 initially as Chief Financial Officer, before becoming Chief Operating Officer and eventually President and Chief Executive Officer, and he served as a member of the board of directors. Mr. McLaughlin began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin received a B.S. in business from Northeastern University and an M.B.A. from Babson College.
高管简历
中英对照 | 中文 | 英文- Brian D. Blakey
BrianD.Blakey自2014年2月以来一直担任Stealth Delaware的首席商务官。此前，Blakey从2010年6月到2014年2月担任Element Marketing Group（一家医疗营销机构）首席战略和运营官，从2006年5月到2010年5月担任Salutria Pharmaceuticals，LLC（前身为Atherogenics Inc.，一家生物技术公司）商业开发Vice President。他也曾担任GlaxoSmithKline公司（制药公司）的多种职务（始于1998年3月），最终担任董事（2003年7月至2004年2月）。Blakey博士持有Pharm.D.来自佛罗里达大学。
Brian D. Blakey has served as Chief Business Officer of Stealth Delaware since February 2014. Previously, Dr. Blakey was the Chief Strategy and Operations Officer of Element Marketing Group, a medical marketing agency, from June 2010 to February 2014 and was the Vice President of Commercial Development at Salutria Pharmaceuticals, LLC formerly AtheroGenics Inc., a biotechnology company, from May 2006 to May 2010. He also worked in multiple roles at GlaxoSmithKline, plc, a pharmaceutical company, beginning in March 1998 ultimately serving in the position of director between July 2003 and February 2004. Dr. Blakey holds a Pharm.D. from the University of Florida.- BrianD.Blakey自2014年2月以来一直担任Stealth Delaware的首席商务官。此前，Blakey从2010年6月到2014年2月担任Element Marketing Group（一家医疗营销机构）首席战略和运营官，从2006年5月到2010年5月担任Salutria Pharmaceuticals，LLC（前身为Atherogenics Inc.，一家生物技术公司）商业开发Vice President。他也曾担任GlaxoSmithKline公司（制药公司）的多种职务（始于1998年3月），最终担任董事（2003年7月至2004年2月）。Blakey博士持有Pharm.D.来自佛罗里达大学。
- Brian D. Blakey has served as Chief Business Officer of Stealth Delaware since February 2014. Previously, Dr. Blakey was the Chief Strategy and Operations Officer of Element Marketing Group, a medical marketing agency, from June 2010 to February 2014 and was the Vice President of Commercial Development at Salutria Pharmaceuticals, LLC formerly AtheroGenics Inc., a biotechnology company, from May 2006 to May 2010. He also worked in multiple roles at GlaxoSmithKline, plc, a pharmaceutical company, beginning in March 1998 ultimately serving in the position of director between July 2003 and February 2004. Dr. Blakey holds a Pharm.D. from the University of Florida.
- James R. Carr
JamesR.Carr自2017年1月起担任Stealth Delaware首席临床开发官，此前自2014年3月起担任临床开发Vice President。在此之前，卡尔博士于2010年10月至2014年3月担任制药公司GlaxoSmithKline plc心血管代谢专营权的执行董事，并于2008年5月至2010年11月担任制药公司方舟生物医药公司临床开发Vice President。Carr博士持有Pharm.D.以及明尼苏达大学（University of Minnesota）药学学士学位。
James R. Carr has served as Chief Clinical Development Officer of Stealth Delaware since January 2017 and previously served as our Vice President, Clinical Development since March 2014. Previously, Dr. Carr was the Executive Director in the Cardiovascular Metabolic Franchise at GlaxoSmithKline plc, a pharmaceutical company, from October 2010 to March 2014 and the Vice President of Clinical Development at ARCA biopharma, Inc., a pharmaceutical company, from May 2008 to November 2010. Dr. Carr holds a Pharm.D. and a B.S. in pharmacy from the University of Minnesota.- JamesR.Carr自2017年1月起担任Stealth Delaware首席临床开发官，此前自2014年3月起担任临床开发Vice President。在此之前，卡尔博士于2010年10月至2014年3月担任制药公司GlaxoSmithKline plc心血管代谢专营权的执行董事，并于2008年5月至2010年11月担任制药公司方舟生物医药公司临床开发Vice President。Carr博士持有Pharm.D.以及明尼苏达大学（University of Minnesota）药学学士学位。
- James R. Carr has served as Chief Clinical Development Officer of Stealth Delaware since January 2017 and previously served as our Vice President, Clinical Development since March 2014. Previously, Dr. Carr was the Executive Director in the Cardiovascular Metabolic Franchise at GlaxoSmithKline plc, a pharmaceutical company, from October 2010 to March 2014 and the Vice President of Clinical Development at ARCA biopharma, Inc., a pharmaceutical company, from May 2008 to November 2010. Dr. Carr holds a Pharm.D. and a B.S. in pharmacy from the University of Minnesota.
- Irene McCarthy
Irene McCarthy自2018年6月起担任Stealth BioTherapeutics Corp董事，自2018年10月起担任Stealth BioTherapeutics Corp首席执行官。她曾一直担任Stealth Delaware公司的首席执行官（2016年2月以来）、Stealth Delaware公司的总裁兼秘书（2015年8月以来）、Stealth Delaware公司的董事（2009年7月以来）。在加入Stealth之前，McCarthy女士于2009年1月至2016年4月担任Morningside Technology Advisory，LLC及其附属公司（一家私人咨询公司）的投资团队成员，她仍担任Morningside Technology Advisory，LLC的董事。她曾担任众多私营生物技术公司的董事，开发广泛的治疗重点领域的药物。她持有宾夕法尼亚大学法学院（the University of Pennsylvania Law School）的法学博士学位和贝茨学院（Bates College）的英语和政治学学士学位。
Irene McCarthy has served as a Director of Stealth BioTherapeutics Corp since June 2018 and as Chief Executive Officer of Stealth BioTherapeutics Corp since October 2018. She has served as Chief Executive Officer of Stealth Delaware since February 2016 as President and Secretary of Stealth Delaware since August 2015 and as a director of Stealth Delaware since July 2009. Prior to Stealth, Ms. McCarthy was a member of the investment team at Morningside Technology Advisory, LLC and affiliates, a private advisory company, from January 2009 to April 2016 and she remains a director of Morningside Technology Advisory, LLC. She has served as a director for numerous private biotechnology companies developing drugs across a broad spectrum of therapeutic focus areas. She holds a J.D. from the University of Pennsylvania Law School and a B.A. in English and Political Science from Bates College.- Irene McCarthy自2018年6月起担任Stealth BioTherapeutics Corp董事，自2018年10月起担任Stealth BioTherapeutics Corp首席执行官。她曾一直担任Stealth Delaware公司的首席执行官（2016年2月以来）、Stealth Delaware公司的总裁兼秘书（2015年8月以来）、Stealth Delaware公司的董事（2009年7月以来）。在加入Stealth之前，McCarthy女士于2009年1月至2016年4月担任Morningside Technology Advisory，LLC及其附属公司（一家私人咨询公司）的投资团队成员，她仍担任Morningside Technology Advisory，LLC的董事。她曾担任众多私营生物技术公司的董事，开发广泛的治疗重点领域的药物。她持有宾夕法尼亚大学法学院（the University of Pennsylvania Law School）的法学博士学位和贝茨学院（Bates College）的英语和政治学学士学位。
- Irene McCarthy has served as a Director of Stealth BioTherapeutics Corp since June 2018 and as Chief Executive Officer of Stealth BioTherapeutics Corp since October 2018. She has served as Chief Executive Officer of Stealth Delaware since February 2016 as President and Secretary of Stealth Delaware since August 2015 and as a director of Stealth Delaware since July 2009. Prior to Stealth, Ms. McCarthy was a member of the investment team at Morningside Technology Advisory, LLC and affiliates, a private advisory company, from January 2009 to April 2016 and she remains a director of Morningside Technology Advisory, LLC. She has served as a director for numerous private biotechnology companies developing drugs across a broad spectrum of therapeutic focus areas. She holds a J.D. from the University of Pennsylvania Law School and a B.A. in English and Political Science from Bates College.
- Robert Weiskopf
Robert Weiskopf自2019年9月起担任Stealth Delaware首席财务官。Weiskopf先生曾于2015年5月至2019年3月担任生物制药公司Arqule，Inc.的首席财务官兼财务主管，并于2007年2月至2015年5月担任Arqule，Inc.的财务Vice President，公司财务总监兼财务主管。Weiskopf先生是一名注册会计师，并持有马萨诸塞大学阿默斯特分校（University of Massachusetts at Amherst）的会计学士学位。
Robert Weiskopf has served as Chief Financial Officer of Stealth Delaware since September 2019. Mr. Weiskopf previously served as Chief Financial Officer and Treasurer of ArQule, Inc., a biopharmaceutical company, from May 2015 to March 2019 and as Vice President of Finance, Corporate Controller, and Treasurer of ArQule, Inc. from February 2007 to May 2015. Mr. Weiskopf is a Certified Public Accountant and holds a B.S.B.A. magna cum laude and M.S.B.A. in accounting from the University of Massachusetts at Amherst.- Robert Weiskopf自2019年9月起担任Stealth Delaware首席财务官。Weiskopf先生曾于2015年5月至2019年3月担任生物制药公司Arqule，Inc.的首席财务官兼财务主管，并于2007年2月至2015年5月担任Arqule，Inc.的财务Vice President，公司财务总监兼财务主管。Weiskopf先生是一名注册会计师，并持有马萨诸塞大学阿默斯特分校（University of Massachusetts at Amherst）的会计学士学位。
- Robert Weiskopf has served as Chief Financial Officer of Stealth Delaware since September 2019. Mr. Weiskopf previously served as Chief Financial Officer and Treasurer of ArQule, Inc., a biopharmaceutical company, from May 2015 to March 2019 and as Vice President of Finance, Corporate Controller, and Treasurer of ArQule, Inc. from February 2007 to May 2015. Mr. Weiskopf is a Certified Public Accountant and holds a B.S.B.A. magna cum laude and M.S.B.A. in accounting from the University of Massachusetts at Amherst.